clinical trial · NCT07323095
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Atom Therapeutics Co., Ltd·phase2·not yet recruiting·n = 80
Chronic Kidney DiseaseABP-671 plus febuxostat Group 1ABP-671 plus febuxostat Group 2ABP-671 GroupPlacebo Group
brief summary
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
started
Jun 30, 2026
primary completion
Oct 31, 2027
completion
Jan 31, 2028
last updated
Apr 22, 2026
official title
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol